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Abstract
 .Previous studies have shown that treatment of rats with 17 a-ethynylestradiol EE causes the appearance in bile of
 .intravenously injected, desialylated ligands, including asialofetuin and low density lipoprotein LDL . Here we show that
 ) . )activated a -macroglobulin a -M , but not insulin, transferrin or acetylated LDL, shows the same phenomenon. a -M2 2 2
appearance in bile in EE-treated rats was inhibited by receptor associated protein, but not unlabelled asialofetuin, strongly
 .  .implicating the a -macroglobulin receptor a MRrLRP receptor in this process. Asialofetuin, apolipoprotein B ApoB of2 2
LDL and a -M) appeared undegraded in the bile of EE-treated but not control rats. When LDL was injected, not only was2
intact apolipoprotein B detected in bile, but the profile of cholesterol esters appearing in bile was characteristic of the
injected human LDL rather than rat lipoproteins. After floatation of the bile on KBr gradients, intact Apo B and cholesterol
esters characteristic of human LDL were found at the normal density of LDL suggesting that the majority of the lipoprotein
particle remains intact. Stimulation of transcytosis was specific to estrogens, and was highest with 17a-ethynylestradiol.
After subcutaneous injection of 0.05 mgrkg body weight of ethynylestradiol, sufficient to give a measurable increase in
transcytosis, the plasma concentration of ethynylestradiol rose to 2.2 nM. Thus estrogen-stimulated transcytosis of
desialylated ligands and a -M) would be expected at physiological estrogen concentrations. q 1997 Elsevier Science B.V.2
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1. Introduction
Pre-menopausal women have a lower incidence of
atherosclerosis compared to men of a similar age,
w xconsistent with a beneficial effect of estrogen 1 .
Following menopause, total and low density lipopro-
 .tein LDL cholesterol levels increase and the risk of
w xatherosclerosis increases 2 . When studied in
ovariectomized, cholesterol fed-rabbits, estrogen ad-
ministration decreased the extent and severity of
w xcoronary atherosclerotic lesions 3 . Two possible
causes of this reduced risk of atherosclerosis have
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been suggested. The first is the plasma cholesterol
lowering effect of estrogens. In rats given pharmaco-
 .logical doses of 17 a-ethynylestradiol EE a pro-
found effect on lipoprotein metabolism has been de-
scribed resulting in a dramatic lowering of total
plasma cholesterol over the first 3 days of treatment
w x4–7 . In humans, estrogen treatment, both in post-
w x w xmenopausal women 8 and in men 9–11 is also
associated with lowered total and LDL plasma
cholesterol levels suggesting that similar mechanisms
occur in humans as in rats. The second possible
anti-atherogenic mechanism of EE is a direct protec-
tive effect on the arterial wall, resulting in reduced
aortic accumulation of lipoprotein. This has been
w x w xobserved in both monkeys 12 and rabbits 13 .
Recently we, and others, have reported another
effect of EE treatment that could account for part of
the lowering of plasma cholesterol levels in EE-treated
w xanimals 14–16 . This involves the intracellular di-
version of LDL from the endocytic pathway, which
would normally result in degradation in lysosomes,
into a transcellular pathway resulting in the discharge
w xof undegraded Apo B into the bile 15,16 . In long-
term experiments, 28% of the injected LDL, mea-
w xsured as Apo B, was observed in the bile 17 . Our
studies have demonstrated that the transcellular
movement of LDL is competitively inhibited in the
presence of excess asialofetuin and is increased by
enzymatic desialylation of LDL in vitro prior to
w xinjection into the animal 16 . These observations
 .suggest that the asialoglycoprotein receptor ASGPR
mediates the transcellular movement of LDL. How-
ever, it has not been determined if the whole LDL
particle, or only the Apo B component of LDL is
transported into the bile.
Other ligands of the ASGPR, like asialo-
orosomucoid and asialofetuin, also appear unde-
graded in the bile in estrogen-treated rats. In one
study the amount of ligand measured in bile in-
creased from 3% in control to 15–23% in estradiol-
w xtreated rats 14 . In this paper we provide further
evidence that this process is receptor mediated, firstly
because a similar phenomenon can be observed with
a -macroglobulin binding to the a -macroglobulin2 2
 .receptor a MRrLRP , and secondly because large2
and complex ligands like LDL appear in bile essen-
tially intact. Secondly we show that the phenomenon
may have physiological relevance because stimula-
tion of transcytosis can be detected at physiological
estrogen concentrations.
2. Materials and methods
2.1. Materials
17a-ethynylestradiol, benzamidine, PMSF, rat
 .transferrin, asialofetuin from foetal calf serum and
Trizma base were obtained from Sigma. Testosterone
acetate, progesterone and b-estradiol-3-benzoate were
from Fluka. Propane-1,2-diol was from Ajax Chemi-
cals, Sydney, Australia. Ethylenediamine tetraacetic
 .acid EDTA , sodium dodecylsulfate, acrylamide and
methylenebisacrylamide were from BDH. Aprotinin
and dithiothreitol were from Boehringer Mannheim.
w 3  .x17a- 6,7- H N -Ethynylestradiol was from NEN.
 .Dimethylsulphoxide DMSO, ACS grade was pur-
chased from ICN.
2.2. Animals
Male Sprague-Dawley rats weighing 180–220 g
were used in all experiments. The animals were fed
ad libitum with standard Purina rat chow. Steroids
were dissolved in propane-1,2-diol at a final concen-
tration of 10 mgrml. The steroids were injected
subcutaneously at a dosage of 5 mgrkg body weight,
unless otherwise specified in the legends to figures, at
24 h intervals for 3 days. Control animals were
injected with equal volumes of propane-1,2-diol.
2.3. Bile duct cannulation
Animals were anaesthetised with nembutal 0.1
.mlr100 g bwt and maintained under anaesthetic
throughout the experiment by periodic application of
metafane. The bile ducts were cannulated with an i.v.
 .catheter needle 0.45 mm I.D.; Terumo, Australia as
w x  7described 16,18 . Radioactive tracers 10 cpm; ap-
.prox. 10 mg protein unless otherwise specified were
injected via the hepatic portal vein. Bile was col-
lected directly from the catheter needle at 15 min
intervals for 2.5 h.
2.4. Preparation of human LDL and rat lipoproteins
Human LDL was prepared on KBr gradients as
w xdescribed by Chung et al. 19 . Rat lipoproteins were
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prepared on a single step KBr gradient as described
w xfor human LDL by Sattler et al. 20 . The band taken
was the most abundant rat protein at a density similar
to human HDL. Human 125I-LDL was re-isolated
from bile as follows. Following cannulation of the
bile duct 125I-LDL was injected into the hepatic
portal vein. Bile was collected directly from the
cannula for 90 min and immediately diluted into 10
mls of nitrogen purged PBS containing 20 mM ben-
zamidine, 25 mg aprotininrml and 1 mM PMSF.
LDL was re-isolated on KBr gradients as described
above.
2.5. Analysis of CqCE in plasma and bile
 .Total plasma cholesterol levels freeqesterified
were determined by de-esterification of the choles-
terol esters followed by enzyme coupled assay of the
 .cholesterol Sigma diagnostic kit 352 . Free choles-
terol and the levels of individual cholesterol esters
were determined in plasma or bile by reversed phase
w xHPLC as described by Kritharides et al. 21 .
2.6. Western blotting
Quantitation of the hepatic LDL receptor was car-
ried out by densitometric scanning of bands obtained
w xby Western blot as described 16 .
2.7. Preparation of a -macroglobulin2
a -Macroglobulin was prepared by the method of2
w xPorath et al. 22 and activated by incubating 1 mg
overnight with 250 ml of 400 mM methylamine, 10
mM citrate, 20 mM sodium phosphate and 50%
glycerol, pH 7.4. It was then extensively dialysed
 .against PBS, pH 7.4 containing 0.1% chelex resin
and shown to be in the activated ‘fast-form’ by
w xnon-denaturing PAGE 23 . Activated a M, desig-2
nated a M), was suspended to 1 mgrml in nitro-2
gen-purged PBS for iodination.
2.8. Iodination of ligands
Proteins were dialysed against PBS before iodina-
w xtion for 1 min using the iodogen method 24 . Iodi-
nated ligands were separated from free iodine on
 .PD-10 columns Pharmacia followed by overnight
dialysis against nitrogen-purged PBS.
2.9. Determination of estrogen plasma concentrations
w3 xPlasma concentrations of H -EE was determined
following subcutaneous injections of 5 mg EErkg
 7 .body weight 7=10 cpmrmmole or 0.05 mg
 9 .EErkg body weight 5=10 cpmrmmole . Plasma
samples were prepared at varying times postinjection
and counted to determine concentrations of radiola-
belled tracer. The proportion of unmetabolised EE in
plasma was then determined by HPLC analysis as
follows. The plasma samples were diluted with an
equal volume of 100% methanol, 0.14 mmol of car-
rier, unlabelled EE was added, and the sample cen-
trifuged at 16 000=g for 5 min. The supernatant
material was passed through Nylon Acrodisk 13 fil-
 .ters 0.2 mm; HPLC grade prior to HPLC analysis.
100 ml of the filtrate was injected onto an LC-18
column 25 cm length, 0.46 cm width, 5 cm guard
.column and eluted from the column with argon-
saturated methanolrwaterrsodium perchloratereth-
 .ylacetate 45:35:5:15 solvent maintained at 508C.
HPLC column fractions were collected and analyzed
for 3H content. Counts associated with the EE peak
were used to estimate the proportions of un-
metabolised EE in plasma. b-Estrogens in plasma
were quantified following subcutaneous injections 5
.mgrkg body weight by radioimmunoassay using the
total estrogens kit from ICN Biomedicals Catalogue
.Number: 07-140202 .
2.10. Miscellaneous procedures
Asialofetuin and human LDL were iodinated by
w xthe iodogen method as described previously 16 .
Protein was determined by the bicinchoninic acid
method using bovine serum albumin as the standard.
3. Results
3.1. Receptors in˝ol˝ed in estrogen-stimulated tran-
scytosis
Estradiol-treatment of male rats has been shown to
cause the transfer of label associated with intra-
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venously injected asialofetuin and LDL into the bile
w x14–16 . In order to investigate the mechanism of this
process we have examined a number of ligands to
determine if the process is receptor mediated, and
 .which receptors are involved Table 1 . As previously
reported, when iodinated ASF was injected into the
hepatic portal vein of EE-treated and control rats a
2.3-fold increase in TCA precipitable radioactivity
could be detected in the bile of the EE-treated ani-
 .mals compared to the control rats Table 1 . The
w125 xinitial rate of appearance of I ASF was increased
w x 1255-fold 16 . A similar result was obtained with I-
labelled methylamine-activated a -macroglobulin2
 ).a M as ligand. In this case the TCA precipitable2
radioactivity collected from the bile of the EE-treated
rats was 3.7-fold higher than the equivalent fraction
 .from control rats Table 1 . The kinetics of transport
w xwere very similar to that reported for asialofetuin 16
with a characteristic lag of approximately 15 min
prior to appearance of TCA precipitable radioactivity
in bile, and peak appearance occurring at 45 min
 .post-injection Fig. 1 . Since only 38% of the injected
) a M was internalised by the liver estimated from2
the total recovery of radioactivity in the liver ho-
.mogenate , about 6% of the ligand internalised by the
liver was diverted to bile in estradiol-treated rats.
Despite its small size, insulin was unable to pass
across parenchymal hepatocytes into the bile of EE-
 .treated animals Table 1 making it unlikely that the
appearance of a -M) or desialylated ligands in bile2
Table 1
The effect of ethynylestradiol administration on appearance of
various ligands in bile
Ligand Bile control Bile EE Fold effect
ASF 3.89"0.82 8.96"1.32 2.3
a2M 0.61"0.21 2.23"0.33 3.7
LDL 0.67"0.04 1.46"0.05 2.2
insulin 2.75"0.82 3.07"0.08 1.11
rat holo-transferrin 0.22"0.055 0.23"0.11 1.05
AcLDL 1.26"0.27 1.15"0.15 0.91
pIgA 28.2"4.5 24.0"6.2 0.86
In all cases male rats were administered 5 mgrkg of EE for 3
7 w125 xdays prior to the experiment. Approximately 10 cpm of I -
labelled ligand were injected into the hepatic portal vein and bile
collected into protease inhibitors over a 90- or 120-min period.
The radioactivity recovered in bile is expressed as a percentage
of injected dose. Three or more animals were used to determine
each value.
Fig. 1. Effect of estrogen on transcytosis of a -macroglobulin2
7 w125 x )into bile. Approximately 10 cpm of I labelled a -M was2
injected into the hepatic portal vein of an anaesthetised rat as
w xpreviously described 20 . The bile duct was cannulated and bile
collected over a 3-h period. Results are expressed as % Injected
 .  .dose ID in each 15 min period of collection A or as cumula-
 .tive counts in the bile B .
was due to paracellular diffusion. Rat holo-transferrin
and acetylated LDL also showed no estradiol stimu-
 .lated appearance in bile Table 1 arguing that the
transferrin receptor and scavenger receptor do not
enter this pathway. Even dimeric immunoglobulin A,
which is normally transported across the cell by the
polymeric immunoglobulin receptor showed no in-
crease with estradiol treatment indicating that the
actual rate of membrane traffic did not increase with
estradiol treatment.
In the case of LDL, the receptor involved was
apparently the ASGPR since LDL appearance in bile
was competed by excess unlabelled asialofetuin and
the initial rate and total amount appearing in bile
could be increased by prior treatment of the LDL
w x )with neuraminidase 16 . The transcytosis of a M2
could not, however, be accounted for by the ASGPR
as transport into the bile of EE-treated rats was not
competed by the co-injection with large amounts of
 .asialofetuin Table 2 . Transport via the a MRrLRP2
was tested by competition with receptor associated
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Table 2
The effect of RAP and asialofetuin on the transcytosis of a M in2
control and EE rats
Injections %ID transcytosed in 2 hours
Control EE
)a M 0.70"0.07 2.62"0.402
)a M q0.18 mg GST-RAP nd 1.13"0.082
)a M q1.2 mg GST-RAP 0.30"0.01 0.79"0.122
)a M q0.5 mg GST nd 2.82
)a M q10 mg asialofetuin 0.81"0.20 2.60"0.602
The bile ducts of control and EE-treated rats were cannulated.
The animals were injected via the hepatic portal vein with
w125 x )  7 .I a M 10 cpmr5 mg protein in the presence and ab-2
sence of the indicated proteins. Bile was collected directly from
the cannula into a cocktail of protease inhibitors on ice. The %ID
refers to cumulative TCA-precipitable radioactivity in bile col-
lected over a 2-h period expressed as a percentage of total
radioactivity injected into the animals. All data represents the
mean and SE of three separate experiments except for co-injec-
tions with GST which was performed once.
ndsnot determined.
 .protein RAP . RAP is a tightly binding, chaperone-
like molecule which specifically associates with, and
blocks the binding of all known ligands to
w xa MRrLRP, even as a GST fusion protein 25 .2
Increasing concentrations of GST-RAP, coinjected
w125 x )with I a M , progressively inhibited the appear-2
ance of TCA-precipitable radioactivity in the bile of
EE-treated rats. A 56% inhibition was observed with
co-injection of 0.18 mg GST-RAP fusion protein and
 .70% with 1.2 mg GST-RAP Table 2 . However GST
alone, when co-injected at a similar concentration,
had no effect on the transcytosis of a M) in EE-rats2
 .Table 2 showing that the effect was specific for the
RAP portion of the fusion protein. These results
indicate that a MRrLRP is responsible for the in-2
creased transcytosis of a M) in EE rats.2
Thus of four receptors tested there was only evi-
dence that two could participate in estrogen-stimu-
lated transport into bile. These were the ASGPR and
a MRrLRP.2
3.2. Ligand is transported into bile without degrada-
tion
Parenchymal hepatocytes have an active transcytic
pathway that normally delivers immunoglobulin A
from the blood into the bile by a receptor-mediated
w xprocess 26 . A characteristic of transcytosis is that
 .the ligands arrive intact at the apical biliary plasma
membrane having escaped degradation in lysosomes.
This was true for all three ligands that we tested of
 w x .the ASGPR and a MRrLRP Ref. 16 ; Fig. 2 . In2
control rats that had not been treated with estradiol
however extensive degradation of any radioactive
material appearing in bile was observed.
Since apolipoprotein B from labelled LDL parti-
cles arrived intact in the bile of EE-treated rats we
went on to investigate whether the complete LDL
particle was capable of estrogen-stimulated transcyto-
sis. We therefore tested to see if LDL particles
arrived in bile in an intact form in EE-treated rats.
Fig. 2. Gel electrophoresis of ligands after transport into the bile.
7 w125 x )  .Approximately 10 cpm of I labelled a -M panel A or2
 .LDL panel B were injected into the hepatic portal vein of
anaesthetised rats. Bile was collected over a 90- min period,
pooled and a sample analysed by SDS PAGE panel A: 10%
.acrylamide, panel B: 5–12% acrylamide . Lane 1: injected lig-
and, lane 2: bile from EE-treated rat, lane 3: bile from control rat,
numbers on side of gel indicate size of marker proteins in kDa.
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Human LDL contains a different profile of CEs than
rat plasma lipoproteins with cholesterol linoleate as
the principle CE. One criterion of intact particle
transport therefore is the appearance in the bile of
CEs characteristic of human LDL. Traffic via lyso-
somes would result in degradation of Apo B protein
and hydrolysis of CEs. In Fig. 3 the HPLC profiles of
 .  .bile before Fig. 3a and after Fig. 3b injection of
human LDL are shown. It can be seen that choles-
terol esters appear in bile in the 60 min collection
period following injection and that the predominant
CE is cholesterol linoleate characteristic of human
LDL. In contrast when rat lipoproteins were injected
the predominant CE found in bile was cholesterol
 .arachidonate Fig. 3c characteristic of the rat
lipoprotein preparation. When the changes in CE
concentration in bile were calculated to allow for the
residual rat cholesterol esters, the changes observed
in biliary CEs showed a strong resemblance to the
injected lipoprotein. This is shown for human LDL in
Fig. 4. The changes in biliary CEs collected from 30
to 90 min after injection compared to bile before
 .injection Fig. 4a resemble the profile of CEs of the
 .injected LDL Fig. 4b but not rat plasma from the
 .same rat Fig. 4c . Free cholesterol shows a negative
change in Fig. 4a because cholesterol secretion into
 .bile is elevated in EE-treated rats Fig. 3a but de-
creases on injection of the human LDL.
The appearance of CEs in bile characteristic of the
injected lipoprotein suggested that whole LDL parti-
cles might be transcytosed across the liver parenchy-
mal cells. We tested this possibility by collecting the
bile from animals injected with iodinated human
LDL and examining the lipoprotein profile after KBr
 .density gradient centrifugation Fig. 5 . As a control
the iodinated LDL was mixed with bile from normal
rats and separated on an identical gradient. The bile
 .from EE-treated rats filled circles, Fig. 5 gave rise
to a peak of radioactivity at a density of 1.05 grcm3.
This corresponded exactly to the density of the hu-
man LDL injectate mixed with bile open squares,
.Fig. 5 . In contrast, when the bile from control
animals was fractionated on KBr gradients, no peak
of radiolabel was found at the density of LDL open
.circles, Fig. 5 .
The material isolated from KBr gradients from
EE-treated rats injected with human LDL was sub-
jected to reversed phase HPLC. Table 3 shows a
Fig. 3. HPLC analysis of biliary cholesterol and cholesterol esters in bile following the intravenous injection of human LDL or rat
lipoproteins. Rats were treated with 5 mg EErkg body weight for 72 h. The bile ducts were cannulated and a bile sample was collected
 .  .  .panel A . After 30 min human LDL 5 mg total cholesterol, panel B or rat lipoprotein 2 mg total cholesterol, panel C was injected via
the hepatic portal vein and bile samples were collected at 30–90 min post-lipoprotein injection. Bile cholesterol and cholesterol esters
were extracted and determined by reversed phase HPLC. Cholesterol esters were identified by their elution time compared to standard
compounds. C, non-esterified cholesterol, CE18:1, cholesterol oleate, CE18:2, cholesterol linoleate, CE 20:4, cholesterol arachidonate.
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Fig. 4. CEs appearing in bile have the same profile as the injected
lipoprotein. Bile was collected from EE-treated rats before and
after injection of human LDL into the hepatic portal vein as
described in Fig. 3 and analysed for C and CE content by HPLC.
Peak areas were quantitated using the peak areas of standards.
The C and CE content of the bile collected after LDL injection
was corrected for the C and CE content of the animal before
injection to give a figure for the net appearance of CEs in bile
 .panel A . In control rats not injected with LDL the C and CE
content of bile did not change over the time course of the
experiment. Panels B and C show the cholesterol and CE content
of the human LDL that was injected and the plasma of EE-treated
rats before injection of human LDL. The data in panel A is the
mean"SE of three separate experiments. C, non-esterified
cholesterol; CE18:1, cholesterol oleate; CE18:2, cholesterol
linoleate; CE 20:4, cholesterol arachidonate.
comparison of the CE profile in this material com-
pared with the human LDL that was injected and
compared with lipoproteins found in the bile of EE-
treated rats before intravenous supplementation with
LDL. It can be seen that the cholesterol ester compo-
sitions of the injected LDL and the material re-iso-
lated from bile were very similar with cholesterol
linoleate the prominent ester injectate 63%; biliary
Fig. 5. Human LDL is transcytosed to bile as an intact particle in
EE-treated rats. Rats were treated for 72 h with 5 mg EErkg
body weight or propane-1,2-diol. The animals were then anaes-
thetised with Nembutal, the bile ducts cannulated, and the ani-
mals injected via the hepatic portal vein with 125I-human LDL
 7 .0.6=10 cpm; 2.7 mg protein . Bile was collected at 30–90 min
post-LDL injection and immediately diluted into 10 mls of
N -purged PBS containing protease inhibitors. It was then made2
up to a density of 1.24 grcm3 in KBr and layered under KBr of
density 1.006 grcm3. Following centrifugation the gradients
 .  .were fractionated and counted. o–o control, v –v bile from
 .EE-treated rats, – human LDL mixed with bile from EE-treated
rat before LDL injection. Approx. 45 000 cpm of the injected
LDL was recovered in the bile from EE-treated rats. The density
 .of each fraction solid line was determined gravimetrically.
Table 3
The cholesterol ester composition of material isolated from bile
on KBr gradients
Bile before Injected LDL LDL in bile
injection
arachidonate 6.1 10.3 9.7
linoleate 27.4 63.0 60.5
oleate 50.7 16.7 22.2
palmitate 15.9 10.0 7.6
Samples of bile were taken from 3 day EE-treated rats before,
and between 30 and 90 min after, intravenous injection of 1.5 mg
of human LDL. The bile collected after injection of LDL was
fractionated by isopycnic centrifugation on a KBr gradient, col-
 .lecting the material at a density of 1.05 grml see Fig. 5 . This
 .material ‘LDL in bile’ was extracted and analysed by reversed
 .phase HPLC. For comparison, human LDL 40 mg protein was
mixed with 0.5 ml of bile from an EE-treated rat and then
subjected to KBr gradient centrifugation and HPLC analysis
 .‘Injected LDL’ . The sample of bile taken before injection of
LDL was extracted and analysed by HPLC without separation on
a KBr gradient.
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.LDL 60.5% wrw . In contrast the cholesterol ester
profile of bile taken from EE-treated animals just
before injection of the human LDL was quite differ-
 .ent with oleate as the major ester 51%, wrw . Thus
the material accumulating in bile has the same buoy-
ant density as human LDL, contains intact apolipo-
protein B, and contains CEs in the same proportion as
the intravenously injected LDL. The simplest expla-
nation for these results is that intact LDL particles are
being transcytosed across the liver hepatocytes into
the bile.
3.3. Stimulation of transcytosis is specific to estro-
gens and occurs at physiological concentration
Fig. 6 shows the effect of several steroids 5
.mgrkg bwt on transcytosis by the ASGPR receptor
 .measured using asialofetuin as ligand and plasma
cholesterol levels. Progesterone and testosterone have
no significant effect on transcytosis or plasma choles-
terol levels. Both b-estrogen and EE stimulate
asialofetuin transcytosis 1.5- and 2.5-fold respec-
.tively over control rats and decrease plasma choles-
Fig. 6. The effect of steroids on plasma cholesterol levels and the
hepatobiliary transcytosis of asialofetuin. Rats were treated with
 .the indicated steroid 5 mgrkg body weight for 72 h. After
treatment plasma samples were prepared and total cholesterol
 .levels were determined shaded boxes . Bile ducts were then
125  7 .cannulated and I-asialofetuin 10 cpm; 10 mg protein was
injected via the hepatic portal vein. Bile samples were collected
 .for 2 h and counted open boxes . All data points are expressed
 .as a percentage of control propane-1,2-diol injected animals and
represent the mean"SE of three separate experiments.
Fig. 7. Plasma estrogen levels following subcutaneous injection
of EE or b-estrogen. Rats were injected with 0.05 mg EErkg
 .body weight A or 5 mg b-estradiol-3-benzoaterkg body weight
 .B . At the indicated times blood samples were removed and the
estrogen concentration determined. Error bars show the means"
SE of three separate experiments.
terol levels to 40% and 10% of control levels,
.respectively . These results suggest that the effects on
asialofetuin transcytosis and plasma cholesterol levels
are specific to estrogens.
To determine if these alterations in lipid
metabolism occur at physiological estrogen concen-
 . w3 xtrations 0.1 to 10 nM in the rat we injected H
17a-ethynylestradiol subcutaneously and determined
the proportion of non-metabolised label in plasma by
HPLC analysis. We have previously reported that
injection of 0.05 mg EErkg body weight produces a
45% reduction in plasma cholesterol levels and 1.7-
w xfold increases in asialofetuin transcytosis 16 . The
maximum plasma EE concentration at this dose was
2.20"0.36 nM and occurred at 1–3 h post-injection
 .Fig. 7a . When EE was used at 5 mg EErkg body
weight a single injection produced a maximum plasma
 .EE level of 220–290 nM data not shown . b-Estro-
gen is effective at stimulating transcytosis via the
ASGPR following subcutaneous administration of 5
mg b-estradiol-3-benzoaterkg body weight. The
maximal b-estrogen level measured by radioim-
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munoassay in plasma under these conditions was
9.0"2.4 nM and occurred at 3 h post-injection Fig.
.7b .
4. Discussion
Previous studies have shown that up to 28% of
w xinjected LDL 17 , or 23% of injected asialo-
w xorosomucoid 14 can appear in the bile of an EE-
treated rat. In these experiments the stimulation in
appearance of biliary ligand due to EE-treatment was
between 1.9- and 5.5-fold depending on the time over
w xwhich bile was collected 14,17 . Although our data
was only for short-term bile collection, due to our
modified operative procedure, we also find a similar
stimulation of 2.2- to 3.7-fold in the appearance of
protein in bile as a result of estradiol treatment. If
measured as intact protein on an SDS gel the stimula-
tion would be considerably larger suggesting that
some of the radioactivity collected in control bile
samples is tca precipitable but not intact. Another
parameter varying the percentage of the injected dose
appearing in bile is the tissue distribution of the
receptor involved. Most of the galactose lectin activ-
w xity is found in the liver 27 with only a small amount
w xfound in macrophages 28 . Thus desialylated ligands
are predominantly cleared by the liver. In contrast
many tissues have receptors for LDL or a -macro-2
globulin thus reducing the amount of ligand that
could appear in the bile. By measuring the amount of
the injected radioactivity associated with the whole
liver at the end of the experiment we estimated that
about 38% of the injected a -macroglobulin is cleared2
by the liver. Allowing for this factor 6% of the
injected dose was transported into bile. Very small
amounts of LDL appear in the bile. A previous
estimate was that 31% of the injected dose is cleared
w xby the liver in rats 17 . However it is presumably
only desialylated LDL that is the ligand for the
ASGPR as the biliary appearance of intact Apo B can
w xbe competed with unlabelled asialofetuin 16 . Our
w x w xearlier studies 29 and those of Taniguchi al 30
have shown that although LDL contains a large
amount of mono desialylated carbohydrate chains,
there is only a very low level of di-desialylated
oligosaccharides in normal LDL. Since oligosaccha-
rides with only one exposed galactose residue have a
Kd for binding to the ASGPR in the mM range,
compared to mM for biantennary galactose residues
w x31 it is not surprising that the clearance of normal
LDL into bile is low. Indeed, the low concentration
of LDL containing di-desialylated oligosaccharides is
presumably a consequence of these being cleared at a
much faster rate than LDL with only mono-desialy-
lated oligosaccharides.
We have provided further evidence in this paper
that the mechanism for appearance of ligand in bile is
receptor mediated transcytosis. Firstly, we have
shown that only ligands of two receptors, the ASGPR
and a MRrLRP, are involved in the process. Other2
much smaller proteins are excluded arguing against
paracellular transport. Furthermore the biliary appear-
ance of intact protein is competed by other ligands of
the receptor in each case. Secondly, we have shown
that the ligand appears in the bile in an undegraded
state, arguing for a process of transcytosis. Surpris-
ingly, this is also true for LDL that is transported into
the bile of EE-treated rats via the ASGPR. Both
protein and cholesterol ester components of the LDL
particle appear in the bile showing a similar fold
increase in EE-treated compared to control animals,
the cholesterol esters isolated from bile retained the
characteristic quantitative relationships of the injected
human LDL rather than that of the endogenous rat
lipoproteins, and the Apo B found in the bile of
EE-treated animals floated at a similar density in a
KBr gradient to normal LDL indicating that the
proteins and lipid components were in a similar
proportion. Some minor rearrangements of the LDL
particles might occur as a result of the high concen-
tration of detergent-like bile acids. Indeed we found
that the particles acquired additional cholesterol con-
sistent with the normally high free-cholesterol level
in bile.
Finally, we have shown that the appearance of
intact ligand in bile is dependent on the administra-
tion of estrogen rather than other sex steroids, and is
measurable at physiological plasma concentrations of
w xestrogen. It has previously been reported 16 that
subcutaneous administration of EE in doses down to
0.05 mgrkg body weight result in significant de-
creases in plasma cholesterol and increases in
asialofetuin transcytosis. This is a dose commonly
used in human hormone replacement therapy. We
show here that the peak venous plasma concentration
( )J.W. Burgess, K.K. StanleyrBiochimica et Biophysica Acta 1359 1997 48–58 57
of intact EE 1h after subcutaneous injection of 0.05
mgrkg body weight in a rat was about 2 nM. b-
estrogen was less effective than EE at reducing plasma
cholesterol and increasing transcytosis of desialylated
ligands presumably because of its high rate of
w xcatabolism 32 . After subcutaneous injection of 5
mgrkg body weight, sufficient to give a significant
increase in transcytosis, a maximal plasma estrogen
concentration of about 9 nM was determined. In the
rat, peak plasma estrogen concentration varies from
about 1 nM in peripheral blood but may be as high as
w x10 nM in adrenal or ovarian venous blood 33 . In
humans, peripheral blood concentrations of estrogens
may be as high as 2 nM just prior to ovulation and
again during the luteal phase. Thus physiological
concentrations of estrogens may have significant
long-term effects on the removal of desialylated lipo-
proteins with only small effects on plasma lipoprotein
concentrations.
Estrogen administration in humans has an anti-
atherogenic effect that has been attributed to either
the beneficial effects of estrogen on plasma lipopro-
w xtein levels 8 or the inhibition of LDL accumulation
w xin the artery wall 12,13 . A third mechanism might
be the removal of desialylated LDL by transcytosis as
described here. Transcytosis could only account for a
part of the cholesterol lowering effect of EE. The
greater proportion of plasma cholesterol is removed
by conversion of lipoprotein-derived cholesterol es-
ters to bile acids. In EE-treated rats this accounts for
the clearance of 55% of exogenously injected human
w xLDL or rat lipoproteins over a 72-h period 34 .
Estrogen-stimulated transcytosis of LDL, however,
may be of importance in that it selectively removes
desialylated forms of LDL.
w x w xLike oxidation 35,36 and glycation 37,38 , desia-
lylation of LDL promotes the accumulation of free
cholesterol and cholesterol esters in macrophage
w x w x29,39 and human aorta intima cells 40–43 . In
healthy subjects approximately 12% of the plasma
LDL pool may exist as desialylated LDL as defined
by binding to lectin columns. This figure increased to
46% in a group of patients with coronary athero-
w xsclerosis 39 . Desialylation has also been shown to
increase the residence time of LDL particles in the
artery wall due to increased binding to matrix compo-
w xnents in the arterial intima 44 . After binding to
proteoglycans LDL has increased ability to promote
w xfoam cell formation 45 . Thus selective removal of
desialylated LDL could also contribute to the de-
creased arterial accumulation of LDL observed in
w xEE-treated rabbits and monkeys 12,13 . This is of
importance because the residence time of LDL in the
artery wall has been identified as the major factor
w xlinked with early events in atherosclerosis 46 . There
are therefore a number of ways in which the selective
removal of desialylated LDL could contribute to the
lower risk of atherosclerosis associated with pre-
menopausal women and hormone replacement ther-
apy in post-menopausal women.
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